Vir Biotechnology (VIR) Return on Sales (2018 - 2026)

Vir Biotechnology has disclosed Return on Sales across 9 years of filings, most recently posting 43.34% for Q1 2026.

• Return on Sales for Q1 2026 came in at 43.34%, down 4294.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.07% (up 21.0% YoY), and the FY2025 annual result was 0.06%, up 1.0% from the prior year.
• Return on Sales came in at 43.34% for Q1 2026 at Vir Biotechnology, down from 0.01% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.0% in Q3 2022 to a low of 43.34% in Q1 2026.
• The 5-year median for Return on Sales is 0.08% (2024), against an average of 3.19%.
• Across the five-year window, Return on Sales soared 86 bps in 2022 and tumbled 4294 bps in 2026, its largest moves.
• Vir Biotechnology's Return on Sales stood at 0.02% in 2022, then sank by 236 bps to 0.07% in 2023, then retreated by 22 bps to 0.08% in 2024, then jumped by 92 bps to 0.01% in 2025, then sank by 646871 bps to 43.34% in 2026.
• The last three Return on Sales figures came in at 43.34% (Q1 2026), 0.01% (Q4 2025), and 6.8% (Q3 2025), per Business Quant data.